Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 128 participants.

Also called NCT03459079

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 128 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03459079
Other papers using this trial's data
  • Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD Journal of hepatology, 2025-06 DOI, PubMed 39824443

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03459079. Randomized; quadruple masking; primary purpose treatment. Start 2018-08-14 (actual); primary completion 2023-04-18 (actual). Results posted on 2024-09-19.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease
Condition
Nonalcoholic Fatty Liver Disease (NAFLD)
Condition
Type 2 Diabetes (T2DM)
Intervention (Drug)
Lanifibranor
Intervention (Other)
Placebo
Lead sponsor
University of Florida (class: other)
Collaborator
Inventiva Pharma (class: industry)

Record details

Record id
cardio:ct-nct03459079
Content hash
13eba13391c258f4ff1d9d3f5d02eb84e910673ec0011c734fab48b21504f1c4